{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:13:02Z","timestamp":1793059982371,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>\n                    Impulse control disorders (ICDs) are less-emphasized adverse effects of dopamine agonists. Evidence on prevalence and predictors of ICDs in patients with prolactinomas is limited and confined chiefly to cross-sectional studies. This was a prospective study performed to investigate ICDs in treatment-na\u00efve patients with macroprolactinomas (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 15) using cabergoline (Group I), compared to consecutive patients of nonfunctioning pituitary macroadenomas (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 15) (Group II). Clinical, biochemical, radiological parameters and psychiatric comorbidities were evaluated at baseline. ICD was assessed by Minnesota impulsive disorder interview, modified hypersexuality and punding questionnaires, South Oaks gambling scale, kleptomania symptom assessment scale, Barratt impulsive scale (BIS), and internet addiction scores (IAS) at baseline and 12 weeks. Group I had a significantly lower mean age (28.5 vs. 42.2 years) with a female predominance (60%) compared to group II. Median tumor volume was lower in group I (4.92 vs. 14 cm\n                    <jats:sup>3<\/jats:sup>\n                    ) despite significantly longer symptom duration (2.13 vs. 0.80 years) than in group II. Serum prolactin decreased by 86% (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.006) and tumor volume decreased by 56% (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.004) at 12 weeks in group I, with a mean weekly cabergoline dose of 0.40 \u00b1 0.13 mg. There was no difference between both groups in hypersexuality, gambling, punding, and kleptomania symptom assessment scale scores at baseline and 12 weeks. Mean BIS showed a more remarkable change in group I (16.2% vs. 8.4%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.051), and 38.5% of patients transitioned from average to above-average IAS in group I. The current study found no increased risk of ICD with short-term use of cabergoline in patients with macroprolactinomas. The use of age-appropriate scores (such as IAS in younger individuals) may help diagnose subtle alterations in impulsivity.\n                  <\/jats:p>","DOI":"10.4103\/0028-3886.370452","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:06:41Z","timestamp":1692850001000},"page":"107-112","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature"],"prefix":"10.4103","volume":"71","author":[{"given":"Ganesh","family":"Sanjan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag K","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Department of Radiology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivashanmugam","family":"Dhandapani","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Sachdeva","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Grover","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000497746","article-title":"Epidemiology and management challenges in prolactinomas","volume":"109","author":"Vroonen","year":"2019","journal-title":"Neuroendocrinology"},{"key":"R3-20250613","first-page":"841","article-title":"Macroprolactinomas: Retrospective follow up study in the MR imaging and correlation with clinical symptomatology","volume":"28","author":"Vaneckova","year":"2007","journal-title":"Neuro Endocrinol Lett"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/07853899809002486","article-title":"Treatment of prolactinomas","volume":"30","author":"Colao","year":"1998","journal-title":"Ann Med"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: Always worth the gamble?","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"R287","DOI":"10.1530\/EJE-18-0667","article-title":"Management of endocrine disease: Impulse control disorders in patients with hyperprolactinemia treated with dopamine agonists: How much should we worry?","volume":"179","author":"Barake","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: A pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and non-functioning pituitary adenomas: A case\u2013control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: A prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: A cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"dgz076","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: Prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1517\/14740338.2016.1151493","article-title":"The safety of treatments for prolactinomas","volume":"15","author":"Auriemma","year":"2016","journal-title":"Exp Opin Drug Saf"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.paid.2009.04.008","article-title":"Fifty years of the Barratt Impulsiveness Scale: An update and review","volume":"47","author":"Stanford","year":"2009","journal-title":"Pers Individ Dif"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/comp.2002.34628","article-title":"Clinical characteristics and associated psychopathology of 22 patients with kleptomania","volume":"43","author":"Grant","year":"2002","journal-title":"Compr Psychiatry"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/cpb.1998.1.237","article-title":"Internet addiction: The emergence of a new clinical disorder","volume":"1","author":"Young","year":"1998","journal-title":"Cyberpsychol Behav"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0165-0327(99)00107-X","article-title":"Psychiatric features of individuals with problematic internet use","volume":"57","author":"Shapira","year":"2000","journal-title":"J Affect Disord"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4103\/0028-3886.299156","article-title":"India's march towards development of treatment for pituitary tumors","volume":"68","author":"Gupta","year":"2020","journal-title":"Neurol India"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s10143-020-01416-x","article-title":"Differential independent impact of the intraoperative use of navigation and angled endoscopes on the surgical outcome of endonasal endoscopy for pituitary tumors: A prospective study","volume":"44","author":"Patil","year":"2021","journal-title":"Neurosurg Rev"},{"key":"R24-20250613","first-page":"314","article-title":"Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline","volume":"134","author":"Walia","year":"2011","journal-title":"Indian J Med Res"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: A complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Safety"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11102-020-01047-x","article-title":"ACTH increment post total bilateral adrenalectomy for Cushing's disease: A consistent biosignature for predicting Nelson's syndrome","volume":"23","author":"Das","year":"2020","journal-title":"Pituitary"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000335996","article-title":"Distinct dopaminergic personality patterns in patients with prolactinomas: A comparison with non-functioning pituitary adenoma patients and age-and gender-matched controls","volume":"96","author":"Athanasoulia","year":"2012","journal-title":"Neuroendocrinology"},{"key":"R29-20250613","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.25557","article-title":"Impulse control disorders and related behaviors in Indian patients with Parkinson's disease","volume":"28","author":"Sarathchandran","year":"2013","journal-title":"Mov Disord"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4103\/0028-3886.263242","article-title":"The predictors of recovery from diabetes mellitus following neurosurgical treatment of acromegaly: A prospective study over a decade","volume":"67","author":"Dutta","year":"2019","journal-title":"Neurol India"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"1044.e5","DOI":"10.1016\/j.wneu.2017.07.111","article-title":"Bevacizumab for Radiation Induced Optic Neuritis Among Aggressive Residual\/Recurrent Suprasellar Tumors: More Than a Mere Antineoplastic Effect","volume":"107","author":"Dutta","year":"2017","journal-title":"World Neurosurg"},{"key":"R32-20250613","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fendo.2018.00453","article-title":"Imatinib Inhibits GH Secretion From Somatotropinomas","volume":"9","author":"Gupta","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R33-20250613","first-page":"315","article-title":"Intracranial tumors: A nurse-led intervention for educating and supporting patients and their caregivers","volume":"23","author":"Thakur","year":"2019","journal-title":"Clin J Oncol Nurs"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.370452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:17:54Z","timestamp":1787836674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.370452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.370452","relation":{},"ISSN":["0028-3886","1998-4022"],"issn-type":[{"value":"0028-3886","type":"print"},{"value":"1998-4022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-04-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}